- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00262860
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with gemcitabine hydrochloride may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with gemcitabine hydrochloride works in treating patients with relapsed or refractory Hodgkin's lymphoma.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Determine the overall response rate (partial and complete response) in patients with relapsed or refractory Hodgkin's lymphoma treated with bortezomib and gemcitabine hydrochloride.
Secondary
- Determine the safety and toxic effects of this regimen in these patients.
- Determine the time to progression in patients treated with this regimen.
- Correlate NF-kB inhibition and proteasome activity with response in patients treated with this regimen.
OUTLINE: This is a multicenter, pilot study.
Patients receive bortezomib IV on days 1, 4, 8, and 11 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 2 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
New York
-
Rochester, New York, Verenigde Staten, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Histologically confirmed Hodgkin's lymphoma
- Recurrent or refractory disease after prior standard combination chemotherapy
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion > 1 cm by physical exam or imaging studies
- No history of non-Hodgkin's lymphoma
- No history of other hematological malignancy
PATIENT CHARACTERISTICS:
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Platelet count ≥ 100,000/mm^3
- Absolute neutrophil count ≥ 1,000/mm^3
Hepatic
- Bilirubin ≤ 2 times upper limit of normal (ULN) (unless due to Gilbert's disease or involvement by Hodgkin's lymphoma)
- AST ≤ 3 times ULN (unless due to involvement by Hodgkin's lymphoma)
Renal
- Creatinine clearance ≥ 30 mL/min
Cardiovascular
- Ejection fraction ≥ 40% by MUGA or echocardiogram (in patients with a history of cardiac disease)
Pulmonary
- Must not require supplemental oxygen therapy
Immunologic
- No known HIV infection
- No uncontrolled bacterial, viral, or fungal infection
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other malignancy requiring therapy
- No peripheral neuropathy ≥ grade 2 within the past 14 days
- No hypersensitivity to boron
- No hypersensitivity to mannitol
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 30 days since prior monoclonal antibody therapy for Hodgkin's lymphoma
- More than 6 months since prior autologous stem cell transplantation
- No prior allogeneic stem cell transplantation
- No concurrent sargramostim (GM-CSF)
- No concurrent pegfilgrastim or filgrastim (G-CSF)
- No concurrent interleukin-11(oprelvekin)
Chemotherapy
- See Disease Characteristics
- More than 30 days since prior chemotherapy for Hodgkin's lymphoma
- No prior treatment with gemcitabine hydrochloride
Endocrine therapy
- More than 30 days since prior corticosteroid therapy for Hodgkin's lymphoma
- No concurrent corticosteroid therapy
Radiotherapy
- More than 30 days since prior radiotherapy for Hodgkin's lymphoma
Other
- No prior treatment with bortezomib
- More than 14 days since prior investigational drugs
- No other concurrent investigational agents
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Bortezomib, Gemcitabine Hdrochloride
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Response Rate After 2 Courses of Therapy
Tijdsspanne: 21 Days/course for up to 2 courses
|
Response was evaluated after two cycles of therapy using the 1999 Cheson response criteria.
All responses were based on CT scans.
The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter by computer-assisted tomography scan.
A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL-who may not have residual disease.
For patients who had FDG-PET imaging, metabolic response was defined as a decrease in the standardized uptake value in target lesions (regions of abnormal FDG uptake on pretreatment FDG-PET images) to below three on posttreatment FDG-PET imaging).
All PET scans were reviewed and interpreted by a single radiologist (SV).
|
21 Days/course for up to 2 courses
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Proteasome Activity Compared to Baseline (Cycle 1)
Tijdsspanne: baseline to 2 hours
|
Peripheral blood (40 ml) was collected on cycle 1, day 1 of prebortezomib at baseline and 2 hrs post-bortezomib treatment.
The samples were refrigerated at 4C and processed within 36 h of collection.
Frozen cell lysates were thawed and the proteasome activity in 10 microliters was determined using a spectroflourometric 20S proteasome assay kit.
Samples were run in triplicate on two separate days.
The percent change between baseline and 2 hrs (day1, cycle 1) was calculated.
|
baseline to 2 hours
|
Change in Proteasome Activity Compared to Baseline (Cycle 2)
Tijdsspanne: baseline and 1-2 weeks after cycle 2, day 11
|
Peripheral blood (40 ml) was collected at baseline and 1-2 weeks after cycle 2, day 11 post-bortezomib treatment.
The samples were refrigerated at 4C and processed within 36 h of collection.
Frozen cell lysates were thawed and the proteasome activity in 10 microliters was determined using a spectroflourometric 20S proteasome assay kit.
Samples were run in triplicate on two separate days.
The percent change between baseline and 2 hrs (day1, cycle 1) was calculated.
|
baseline and 1-2 weeks after cycle 2, day 11
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jonathan W. Friedberg, MD, James P. Wilmot Cancer Center
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Lymfoom
- Ziekte van Hodgkin
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Enzymremmers
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Gemcitabine
- Bortezomib
Andere studie-ID-nummers
- CDR0000448635
- URCC-U9404
- URCC-RSRB-10368
- MILLENNIUM-VEL-03-079
- LILLY-B9E-US-X433
- DFCI-04388
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op gemcitabine hydrochloride
-
Dokuz Eylul UniversityNog niet aan het wervenBlaaskanker | Gemcitabine | BCG | Docetaxel | Intravesicale instillatieKalkoen
-
Insel Gruppe AG, University Hospital BernSwiss Cancer LeagueNog niet aan het werven
-
German Society for Pediatric Oncology and Hematology...Deutsche Krebshilfe e.V., Bonn (Germany)WervingNasofarynxcarcinoom | Nasofaryngeale kanker | Nasofarynxkanker | Nasofaryngeale neoplasmataDuitsland